Abstract
Get full access to this article
View all access options for this article.
References
1.
Precision BioSciences. Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease. June 21, 2022. https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-vivo-gene-editing-collaboration (Last accessed
July 14 , 2022
).
2.
Philippidis, A. Beyond CRISPR: Precision Bio Lands Up-to-$1.5B Editing Deal with Novartis. Genetic Engineering & Biotechnology News. June 30, 2022. https://www.genengnews.com/topics/genome-editing/beyond-crispr-precision-bio-lands-up-to-1-5b-editing-deal-with-novartis/ (Last accessed
July 14 , 2022
).
3.
Longfellow Real Estate Partners and The University of Pennsylvania. Longfellow Real Estate Partners with the University of Pennsylvania to Develop 455,000 sq.ft. Life Sciences Research, Development and Manufacturing Facility. June 9, 2022. https://www.pennovation.upenn.edu/sites/default/files/pdfs/release_-_longfellow_enters_philadelphia_market_at_pennovation_works_06-09-22.pdf (Last accessed
July 14 , 2022
).
4.ESI Econsult Solutions Inc . 2022 Greater Philadelphia Cell and Gene Therapy Update, Prepared for CEO Council for Growth and the University City Science Center. June 2022. http://legacy.chamberphl.com/download/public/2022-cell-and-gene-therapy-talent-report62822.pdf (Last accessed
July 14 , 2022
).
5.
Mogrify and Astellas Pharma. Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss. July 5, 2022. https://mogrify.co.uk/mogrify-and-astellas-announce-collaboration-to-conduct-research-on-in-vivo-regenerative-medicine-approaches-to-address-sensorineural-hearing-loss/ (Last accessed
July 14 , 2022
).
6.
BioMarin Pharmaceutical. BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A. June 24, 2022. https://investors.biomarin.com/2022-06-24-BioMarin-Receives-Positive-CHMP-Opinion-in-Europe-for-Valoctocogene-Roxaparvovec-Gene-Therapy-to-Treat-Adults-with-Severe-Hemophilia-A (Last accessed
July 14 , 2022
).
7.
Carbon Biosciences. Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline. June 21, 2022. https://www.businesswire.com/news/home/20220621005289/en/Carbon-Biosciences-Launches-with-38-Million-Series-A-Financing-to-Advance-Novel-Gene-Therapy-Platform-and-Pipeline (Last accessed
July 14 , 2022
).
8.
Code Biotherapeutics. Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases. June 7, 2022. https://www.businesswire.com/news/home/20220607005030/en/Code-Biotherapeutics-Raises-Upsized-and-Oversubscribed-75-Million-in-Series-A-Financing-to-Develop-Therapies-for-Debilitating-Genetic-Diseases (Last accessed
July 14 , 2022
).